Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNFTNYSE:PRMENYSE:RCORNASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNFTGenfit$4.23-2.5%$3.75$2.55▼$6.42$211.48M0.9214,726 shs4,264 shsPRMEPrime Medicine$1.29+4.9%$1.52$1.11▼$8.14$169.37M1.91.33 million shs2.00 million shsRCORRenovacor$3.20$3.07$1.34▼$9.74$55.26M-0.2830,033 shsN/ASLDBSolid Biosciences$2.81-2.8%$3.28$2.41▼$10.37$217.82M2.321.08 million shs871,960 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNFTGenfit-2.53%+0.95%+16.18%+11.17%-4.73%PRMEPrime Medicine+4.88%-18.87%-27.53%-56.42%-82.68%RCORRenovacor0.00%0.00%0.00%0.00%0.00%SLDBSolid Biosciences-2.77%+1.44%-21.07%-51.38%-66.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNFTGenfit0.953 of 5 stars3.52.00.00.00.00.00.0PRMEPrime Medicine3.6882 of 5 stars4.40.00.00.02.33.31.3RCORRenovacorN/AN/AN/AN/AN/AN/AN/AN/ASLDBSolid Biosciences4.1702 of 5 stars4.64.00.00.02.63.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNFTGenfit 3.00Buy$13.00207.33% UpsidePRMEPrime Medicine 2.86Moderate Buy$11.80814.73% UpsideRCORRenovacor 0.00N/AN/AN/ASLDBSolid Biosciences 3.23Buy$14.90430.25% UpsideCurrent Analyst Ratings BreakdownLatest RCOR, SLDB, GNFT, and PRME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$16.005/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.005/19/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/16/2025SLDBSolid BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.005/16/2025SLDBSolid BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $10.005/16/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$18.00 ➝ $17.005/13/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/20/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNFTGenfit$67.00M3.16N/AN/A$1.48 per share2.86PRMEPrime Medicine$3.85M44.04N/AN/A$1.37 per share0.94RCORRenovacorN/AN/AN/AN/A$2.47 per shareN/ASLDBSolid Biosciences$8.09M26.92N/AN/A$6.27 per share0.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/AN/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/ARCORRenovacor-$14.10M-$0.73N/AN/AN/AN/A-62.88%-48.90%N/ASLDBSolid Biosciences-$96.01M-$2.99N/AN/AN/AN/A-58.75%-47.84%8/12/2025 (Estimated)Latest RCOR, SLDB, GNFT, and PRME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SLDBSolid Biosciences-$0.53-$0.59-$0.06-$0.59N/AN/A3/7/2025Full YearPRMEPrime MedicineN/A-$1.65N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNFTGenfitN/AN/AN/AN/AN/APRMEPrime Medicine$1.45112.09%N/AN/A N/ARCORRenovacorN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNFTGenfit0.613.743.74PRMEPrime MedicineN/A6.506.50RCORRenovacorN/A6.606.60SLDBSolid BiosciencesN/A7.857.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNFTGenfit2.24%PRMEPrime Medicine70.37%RCORRenovacor45.84%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipGNFTGenfit4.20%PRMEPrime Medicine23.47%RCORRenovacor14.40%SLDBSolid Biosciences1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNFTGenfit12050.00 million47.90 millionNot OptionablePRMEPrime Medicine234131.29 million100.38 millionOptionableRCORRenovacor1917.27 million14.78 millionNot OptionableSLDBSolid Biosciences10077.52 million35.05 millionOptionableRCOR, SLDB, GNFT, and PRME HeadlinesRecent News About These CompaniesSolid Biosciences (NASDAQ:SLDB) Earns "Overweight" Rating from Cantor FitzgeraldMay 24 at 10:49 AM | marketbeat.comChardan Capital Has Lowered Expectations for Solid Biosciences (NASDAQ:SLDB) Stock PriceMay 21 at 8:45 AM | marketbeat.comQ1 Earnings Forecast for SLDB Issued By William BlairMay 21 at 3:31 AM | marketbeat.comWedbush Cuts Solid Biosciences (NASDAQ:SLDB) Price Target to $17.00May 19, 2025 | americanbankingnews.comBarclays Cuts Solid Biosciences (NASDAQ:SLDB) Price Target to $10.00May 19, 2025 | americanbankingnews.comTruist maintains buy on Solid Biosciences stock, price target at $16May 18, 2025 | investing.comDimensional Fund Advisors LP Purchases 192,714 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)May 18, 2025 | marketbeat.comPiper Sandler Has Lowered Expectations for Solid Biosciences (NASDAQ:SLDB) Stock PriceMay 18, 2025 | americanbankingnews.comWhen Might Solid Biosciences Run Out Of Money?May 17, 2025 | finance.yahoo.comSolid Biosciences (NASDAQ:SLDB) Upgraded by Cantor Fitzgerald to "Strong-Buy" RatingMay 17, 2025 | marketbeat.comSolid Biosciences Inc.: Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 16, 2025 | finanznachrichten.deSolid Biosciences (NASDAQ:SLDB) Stock Rating Upgraded by Cantor FitzgeraldMay 16, 2025 | americanbankingnews.comSolid Biosciences (SLDB) Expected to Announce Earnings on WednesdayMay 16, 2025 | marketbeat.comSolid Biosciences files for $400M mixed securities shelf offeringMay 16, 2025 | msn.comSolid Biosciences Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 15, 2025 | globenewswire.comSolid Biosciences (SLDB) to Release Earnings on WednesdayMay 14, 2025 | americanbankingnews.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Buy" by BrokeragesMay 4, 2025 | marketbeat.comWhy Solid Biosciences Inc.’s (SLDB) Stock Is Up 10.82%May 3, 2025 | aaii.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comSolid Biosciences to Present Phase 1/2 Trial Data for SGT-003 Gene Therapy at ASGCT 2025 Annual MeetingMay 1, 2025 | nasdaq.comSolid Biosciences to Participate at The Citizens Life Sciences ConferenceApril 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCOR, SLDB, GNFT, and PRME Company DescriptionsGenfit NASDAQ:GNFT$4.23 -0.11 (-2.53%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$4.64 +0.41 (+9.67%) As of 05/23/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Prime Medicine NYSE:PRME$1.29 +0.06 (+4.88%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.28 -0.01 (-1.09%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Renovacor NYSE:RCORRenovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.Solid Biosciences NASDAQ:SLDB$2.81 -0.08 (-2.77%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.82 +0.01 (+0.36%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
